# Stage 2 Product UX validation

Point-in-time documentation/governance validation record. Scope: [Stage 2 authorization](https://github.com/abuhmaid28/egyhealth360/issues/72#issuecomment-6565142946) and the explicit Product Owner Stage 2 request. Base: **`7156b7fe667342a2ed4b356d857ff56c2f7da7fa`**. Exact final head/PR and remote CI run details belong in the PR handoff so this file does not claim validation of its own not-yet-created commit.

## Scope and evidence method

The new current reading path is current authorization → AGENTS → [CURRENT_STATUS](CURRENT_STATUS.md) → [charter](FOUNDATION_CHARTER.md) + [source index](SOURCE_OF_TRUTH.md) → [UX_FOUNDATION](UX_FOUNDATION.md) → [USER_JOURNEYS](USER_JOURNEYS.md) → [UX_DECISION_REGISTER](UX_DECISION_REGISTER.md). [Inventory](PRODUCT_UX_INVENTORY.md) supplies traceable current/V1 evidence; code/contracts are optional deeper verification, not necessary to answer the product questions below.

Stage 2 creates five documents (foundation, journeys, decisions, inventory, validation) and reconciles README, CURRENT_STATUS, SOURCE_OF_TRUTH, IMPLEMENTATION_ROADMAP, PROJECT and the UX entrypoint. No accepted clinical/security/product contract is edited. In particular PRODUCT.md's old task sentence is explicitly subordinated in the source index rather than changing a high-risk policy file for cosmetic freshness.

Verification uses the existing repository docs checker and CI-policy tests, complete base-to-candidate whitespace/classification checks and Git object/working-tree byte comparison. No new tests or dependencies, screenshot regeneration, frontend build, PostgreSQL, Docker or browser lane is warranted for the Stage 2 diff. CI must independently select DOCS_GOVERNANCE and explicitly skip heavy lanes. A policy mismatch must be diagnosed, not accepted or worked around.

## Fresh-agent comprehension simulation

**Method:** second-pass self-simulation as a fresh product/design reader, limited to the current reading path above. This is **not an independently staffed review**, an empirical usability study or owner approval. Each answer is checked against an explicit product-document section, with current/future and recommendation/approval distinctions retained. The required independent Stage 2 review remains next.

| # | Question | Answer from the new path | Location |
| --- | --- | --- | --- |
| 1 | Who are the five user groups? | Patient, Clinician, Pharmacy Staff, Laboratory Staff, Admin | Foundation §1 |
| 2 | What does each primarily seek? | Patient: find/receive/understand care and next action. Clinician: today's safe consultation and communicated outcome. Pharmacy: exact authorized full-item supply. Future Lab: assigned tests and verified/corrected result. Admin: legitimate operational access/configuration | Foundation §1–2 |
| 3 | Patient P0 tasks? | P01 enter own care; P02 find/select clinician/time; P03 book; P04 understand visit/next action; P05 released outcome/follow-up; P06 signed prescription/fulfillment. P11 final results is explicitly FUTURE P0 | Foundation §3 Patient |
| 4 | Clinician P0 tasks? | C01 schedule; C02 context/authority/open; C03 review/document; C04 explicitly release summary; C05 prescribe if needed; C06 follow-up if needed plus review/close. C13 diagnostics/results is FUTURE P0 | Foundation §3 Clinician |
| 5 | Pharmacy P0 tasks? | F01 exact queue, F02 inspect/accept, F03 exact full-item dispense, F04 reconcile committed/uncertain result and remaining work. Current backend, Live UI gap | Foundation §3 Pharmacy |
| 6 | Is Lab implemented? | No. Accepted future policy and Demo presentation exist; no Lab backend or Live delivery | Foundation §1, J5 |
| 7 | Full healthcare continuity? | Booking → authorized consultation → documentation/released outcome → optional prescription/pharmacy and independently optional FUTURE diagnostic order/Lab → follow-up → permitted histories/FUTURE I4 integration. Not a compulsory serial chain or an EACCE prerequisite | J7 |
| 8 | Major cross-role handoffs? | Patient authorization→clinician acceptance; booking→clinician visit; clinician release→patient action; clinician exact routing→pharmacy acceptance/supply; FUTURE order→Lab finalization→patient/current clinician; follow-up recommendation→patient booking→explicit clinician linkage. Admin only operational support | J1–J7, J7 closing paragraph |
| 9 | What should Patient see immediately? | Task-appropriate own/visit identity, clinician/clinic/time/timezone/status and permitted next action; released instructions/follow-up; exact signed medication/instructions/validity/fulfillment when relevant. No private/draft counts or unsupported results | Foundation §2 Patient |
| 10 | What should Clinician see during consultation? | Correct patient/visit/clinic, current access/consultation state, private-versus-summary purpose, save/sign/release state, findings/allergy uncertainty and relevant permitted context; exact prescription and prior supply when prescribing. Older detail on demand | Foundation §2 Clinician, J2 |
| 11 | What must Pharmacy not access generally? | Patient records/profiles, consultations/private notes, unrelated routes/providers; completed-history purpose also excludes patient name/source instructions. Only current exact artifact/purpose scope | Foundation §2 Pharmacy, J3 |
| 12 | What must Admin not imply? | Clinical payload/forensic browsing, consent/assignment manufacture, impersonation, signing, dispensing, result finalization or break-glass | Foundation §2 Admin/§5, J6 |
| 13 | Governing UX principles? | U01 human intention/precision; U02 explicit state/responsibility; U03 complete tasks; U04 progressive detail with safety context; U05 continuity within access; U06 deliberate consequences; U07 uncertainty honesty; U08 source/history truth; U09 language parity; U10 relevant attention/trust. Proposed framing; inherited safety clauses binding | Foundation §4, decision status definitions |
| 14 | V1 anti-patterns to avoid? | Repeated/equal card emphasis, feature-dump dashboards, backend jargon, awkward personal role labels, English leakage, patient overload/clinician context loss, task fragmentation, hidden status/next action, future-as-Live, Admin overreach, decorative counts and duplicated facts; observed versus anticipated distinguished | Foundation §7 |
| 15 | Is navigation finalized? | No sidebar/bottom nav, sitemap, final grouping/page hierarchy or navigation labels chosen. Existing path inventory is evidence only | Foundation §6, UXD21 |
| 16 | Is Arabic terminology finalized? | No. Requirements for natural Arabic, parity and localized status/time are defined; exact glossary/microcopy/wording owner-gated later | U09, UXD16/UXD22 |
| 17 | Is visual design chosen? | No logo/colors/fonts/radii/shadows/cards/icons/illustration/component appearance/layout selected; V1 is BEFORE evidence | Foundation §6, UXD23 |
| 18 | May Codex design/implement final UI now? | No. This is Product UX definition; approved UX/content/brand/Design System/prototypes and later architecture/implementation authorization are required | Foundation §8, charter |
| 19 | What should Stage 3 solve? | Goal/task grouping, discoverable entry/relationship prerequisites, role-specific hierarchy, contextual continuity, current/future exposure and safe paths, then proposed navigation/sitemap/page structure for owner review; no automatic start | Foundation §6, UXD21 |
| 20 | What needs Product Owner approval next? | Accept/revise role/task/journey/principle package; choose later integration emphasis/sequence where V1 is incomplete; authorize bounded Stage 3 only after independent review and health review. Final content/visual choices remain later gates | UXD18–UXD20 and explicit deferrals |

**Result: 20/20 clear in the second-pass simulation.** No backend reconstruction was required for these answers. This is a comprehension check, not permission to mark recommendations approved or skip independent review.

## Whole-project health review inputs

| Area | Stage 2 disposition / limit |
| --- | --- |
| Current truth and governance | Current authorization and entrypoints reconciled; accepted contract bodies preserved; older task context explicitly subordinated |
| Product / UX / content | Five role profiles, classified tasks, seven journey models, ten principles, evidence-labeled anti-patterns and three material owner decisions. Rankings/frequencies and experience framing remain proposals |
| Design / frontend architecture | V1 screenshots and runtime byte-preserved; no final design or architecture accepted. Existing context/i18n/shared-component debt remains for later gates |
| Backend / security / data | No changes or new clinical policy. Authority, privacy, history, replay and full-item semantics retained. No fresh security/runtime audit claimed |
| CI / testing | Existing risk classifier/checker/gate used. Actual final PR and baseline-main evidence required in handoff; no heavy suites intentionally run for docs |
| Deployment | No deployment/database/domain operation; hosted I2 evidence retained, exact-main/I3 parity unverified. Protected final domain untouched |
| Debt and next-stage readiness | Entry/relationship and I3 UI gaps, terminology/repetition, incomplete integrated history recorded. No new concrete P0/P1 foundation defect established; accepted Stage 1.5-not-required disposition retained. Owner/independent review must assess Stage 2 before separately authorizing Stage 3 |

This supplies review inputs, not a claim that independent milestone health review or Product Owner approval has already occurred.

## Validation and CI evidence

Local candidate checks: **PASS**.

| Check | Result |
| --- | --- |
| Existing CI policy/CLI/gate tests | 30/30 pass, zero failures/skips/cancellations |
| Complete changed-path classification | DOCS_GOVERNANCE only; full=false; only docs-check selected; no application/runtime/audit lane selected |
| Current plus changed Markdown reference/classification checks | 437 local references across 27 current/changed documents pass |
| Complete base-to-candidate whitespace and scope | 11 Markdown files only; whitespace passes |
| Byte preservation against base | All 580 other tracked base files identical, including runtime/frontend/UI/CSS/assets, schema/migrations/OpenAPI, accepted contracts, dependencies/config/CI/tests and historical evidence |
| Historical screenshots/reports | All 91 files under docs/ui-screenshots unchanged; doctor-demo subset 18 files / 2,560,222 bytes; tree c4abdc4430d581ef2c5c136ff78066c66da5a2d0 |
| Product reading-path simulation | 20/20 questions answerable; independent review still required |

The final PR handoff records exact head/base, selected remote CI plan, job results/durations and overall elapsed time. No successful check is inferred from a pending run.

Post-merge CI Accelerator run: [41359576936](https://github.com/abuhmaid28/egyhealth360/actions/runs/41359576936), push/main at the base above. Full validation is expected for that infrastructure merge. Its status is rechecked at handoff; a genuine regression blocks the review-ready verdict. Stage 2 may be authored in parallel.

Delivery remains one PR on `docs/foundation-reboot-v2-stage2-product-ux`, OPEN / UNMERGED / auto-merge OFF. Final technical readiness and independent Product UX approval are separate. Do not begin Stage 3.
